Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer

Abiraterone and enzalutamide are high‐cost oral therapies that increasingly are used to treat patients with advanced prostate cancer; these agents carry the potential for significant financial consequences to patients. In the current study, the authors investigated coping and material measures of the financial hardship of these therapies among patients with Medicare Part D coverage.

[1]  Marizen R. Ramirez,et al.  Rural Counties With Majority Black Or Indigenous Populations Suffer The Highest Rates Of Premature Death In The US. , 2019, Health affairs.

[2]  T. Stinchcombe,et al.  The Association Between Medicare Low-income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer. , 2019, Journal of the National Cancer Institute.

[3]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[4]  Ryan D. Ross,et al.  Adoption of Abiraterone and Enzalutamide by Urologists. , 2019, Urology.

[5]  Dana P Goldman,et al.  Racial and ethnic disparities in medication adherence among privately insured patients in the United States , 2019, PloS one.

[6]  M. Rosenzweig,et al.  Predictors of Adherence and Treatment Delays among African American Women Recommended to Receive Breast Cancer Chemotherapy. , 2018, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[7]  A. Deal,et al.  Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. , 2018, Journal of oncology practice.

[8]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[9]  V. Shankaran,et al.  Impact of trained oncology financial navigators on patient out-of-pocket spending. , 2018, The American journal of managed care.

[10]  H. Linden,et al.  Pilot Feasibility Study of an Oncology Financial Navigation Program. , 2017, Journal of oncology practice.

[11]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[12]  F. Camacho,et al.  Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors , 2017, Medicine.

[13]  H. Linden,et al.  Development of a financial literacy course for patients with newly diagnosed cancer. , 2017, The American journal of managed care.

[14]  R. Osarogiagbon,et al.  Evolution in the Surgical Care of Patients With Non-Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort. , 2017, Seminars in thoracic and cardiovascular surgery.

[15]  Matthew P. Banegas,et al.  Financial Hardships Experienced by Cancer Survivors: A Systematic Review , 2017, Journal of the National Cancer Institute.

[16]  B. Thompson,et al.  The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients , 2016, American journal of clinical oncology.

[17]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Keating,et al.  Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Salloum,et al.  Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors , 2016, Journal of Cancer Survivorship.

[20]  C. White,et al.  Roles of prices, poverty, and health in Medicare and private spending in Texas. , 2015, American Journal of Managed Care.

[21]  Spencer E. Harpe,et al.  Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly , 2014, Journal of managed care & specialty pharmacy.

[22]  A. Abernethy,et al.  Patient-oncologist cost communication, financial distress, and medication adherence. , 2014, Journal of oncology practice.

[23]  Sarah T. Hawley,et al.  Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Birkmeyer,et al.  Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. , 2013, Health affairs.

[25]  A. Abernethy,et al.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. , 2013, The oncologist.

[26]  M. Eaddy,et al.  Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence , 2012, Patient preference and adherence.

[27]  S. Kripalani,et al.  Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. , 2012, Journal of hospital medicine.

[28]  A. Farmer,et al.  An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes , 2012, BMC Family Practice.

[29]  S. Lee,et al.  Racial differences in medication adherence: A cross-sectional study of Medicare enrollees. , 2010, The American journal of geriatric pharmacotherapy.

[30]  Jill Waalen,et al.  A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. , 2009, The American journal of managed care.

[31]  J. Haas,et al.  Race/Ethnicity and Nonadherence to Prescription Medications Among Seniors: Results of a National Study , 2007, Journal of General Internal Medicine.

[32]  B. Briesacher,et al.  Exploring racial and ethnic disparities in prescription drug spending and use among Medicare beneficiaries. , 2006, The American journal of geriatric pharmacotherapy.

[33]  J. Birkmeyer,et al.  Race and Surgical Mortality in the United States , 2006, Annals of surgery.

[34]  J. Iglehart.  The Centers for Medicare and Medicaid Services. , 2001, The New England journal of medicine.

[35]  R. Osarogiagbon,et al.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non–Small Cell Lung Cancer After Resection With Curative Intent , 2018, JAMA oncology.

[36]  Xianglin L. Du,et al.  Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Borders,et al.  Racial and ethnic disparities in the financial burden of prescription drugs among older Americans. , 2007, Journal of health and human services administration.

[38]  S. Leslie.  Using Arrays to Calculate Medication Utilization , 2005 .